Wall Street analysts expect Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) to report sales of $1.02 million for the current quarter, Zacks reports. Two analysts have provided estimates for Aethlon Medical’s earnings, with the lowest sales estimate coming in at $40,000.00 and the highest estimate coming in at $2.00 million. Aethlon Medical reported sales of $30,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 3,300%. The company is expected to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Aethlon Medical will report full-year sales of $1.46 million for the current year, with estimates ranging from $320,000.00 to $2.60 million. For the next financial year, analysts expect that the business will post sales of $95.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Aethlon Medical.
Several research analysts have commented on the stock. StockNews.com initiated coverage on shares of Aethlon Medical in a report on Saturday. They issued a “sell” rating for the company. Maxim Group cut their target price on shares of Aethlon Medical from $11.00 to $4.00 in a research note on Tuesday, February 15th.
NASDAQ:AEMD opened at $1.61 on Tuesday. The firm has a market cap of $24.81 million, a price-to-earnings ratio of -2.68 and a beta of 0.81. Aethlon Medical has a 52 week low of $0.88 and a 52 week high of $12.49. The firm has a 50-day moving average price of $1.25 and a two-hundred day moving average price of $1.67.
About Aethlon Medical (Get Rating)
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.
- Get a free copy of the StockNews.com research report on Aethlon Medical (AEMD)
- Palo Alto Networks Bottoms But A Rebound May Not Be Coming
- Stock Market Downgrades Are Dragging The S&P 500 Lower
- Under Armor Stock is Getting Undervalued
- Time to Ring the Register on Funko Stock
- The Institutions Go Long Saia, Inc In Q2
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.